Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies.

Literature DB >> 28091975

Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies.

Andrew Kwong¹, Martina Sanlorenzo², Klemens Rappersberger³, Igor Vujic^4,5.

Abstract

Early stage melanomas can achieve remarkable outcomes with surgery alone, but stage IV metastatic melanoma requires significant intervention and has poor outcomes. Here we present evidence on the latest advances in melanoma treatment, discuss the scientific concepts behind new therapies, and analyze the potential of future treatment combinations.

Entities: Disease

Keywords: Efficacy; Immunotherapy; Malignant melanoma; Targeted molecular therapy; Therapy

Mesh：

Year: 2017 PMID： 28091975 DOI： 10.1007/s10354-016-0535-1

Source DB: PubMed Journal: Wien Med Wochenschr ISSN： 0043-5341

62 in total

1. Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors: Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal: N Engl J Med Date: 2012-06-04 Impact factor: 91.245

2. Hepatotoxicity with combination of vemurafenib and ipilimumab.

Authors: Antoni Ribas; F Stephen Hodi; Margaret Callahan; Cyril Konto; Jedd Wolchok
Journal: N Engl J Med Date: 2013-04-04 Impact factor: 91.245

3. Improved survival with ipilimumab in patients with metastatic melanoma.

Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245

4. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors: James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal: Clin Cancer Res Date: 2011-12-12 Impact factor: 12.531

5. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.

Authors: Martina Sanlorenzo; Aditi Choudhry; Igor Vujic; Christian Posch; Kim Chong; Katia Johnston; Melissa Meier; Simona Osella-Abate; Pietro Quaglino; Adil Daud; Alain Algazi; Klemens Rappersberger; Susana Ortiz-Urda
Journal: J Am Acad Dermatol Date: 2014-10-16 Impact factor: 11.527

Review 6. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

Authors: Gretchen A Repasky; Emily J Chenette; Channing J Der
Journal: Trends Cell Biol Date: 2004-11 Impact factor: 20.808

7. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245

Review 8. Dabrafenib and its potential for the treatment of metastatic melanoma.

Authors: Alexander M Menzies; Georgina V Long; Rajmohan Murali
Journal: Drug Des Devel Ther Date: 2012-12-11 Impact factor: 4.162

9. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.

Authors: Maria Colombino; Amelia Lissia; Mariaelena Capone; Vincenzo De Giorgi; Daniela Massi; Ignazio Stanganelli; Ester Fonsatti; Michele Maio; Gerardo Botti; Corrado Caracò; Nicola Mozzillo; Paolo A Ascierto; Antonio Cossu; Giuseppe Palmieri
Journal: J Transl Med Date: 2013-08-29 Impact factor: 5.531